Every 8-K that Organogenesis Holdings Inc. (ORGO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ORGO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ORGO filings page.
Organogenesis Holdings Inc. entered into an at-the-market Sales Agreement with BTIG, LLC and Citizens JMP Securities, LLC, allowing it to offer and sell shares of its Class A common stock having an aggregate offering price of up to $75,000,000 from time to time through the agents.
The shares are offered under a previously filed shelf registration statement on Form S-3 (No. 333-281392), filed with the SEC on August 8, 2024 and declared effective on August 15, 2024, pursuant to a prospectus supplement dated August 6, 2026. Sales may be made as “at the market offerings” under Rule 415(a)(4), including on the Nasdaq Capital Market. Organogenesis will pay the agents a commission of up to 3.0% of the gross sales price per share, has no obligation to sell any shares, and the offering will terminate upon termination of the Sales Agreement in accordance with its terms.
Organogenesis Holdings Inc. reported substantially weaker results for the quarter and six months ended June 30, 2026. Second‑quarter net product revenue fell to $42.8 million from $100.8 million, a 58% decline, led by a 61% drop in Advanced Wound Care revenue to $36.1 million; Surgical & Sports Medicine declined 18% to $6.7 million.
Gross profit fell to $19.1 million, or 45% of net product revenue, from $73.1 million, or 73%. Operating expenses decreased 17% to $94.7 million as selling, general and administrative costs were reduced while R&D increased. Operating loss widened to $51.0 million and net loss to $96.3 million, or $(0.77) per share. Adjusted net loss was $89.0 million and Adjusted EBITDA loss $34.4 million.
For the first half of 2026, net product revenue was $79.1 million versus $187.5 million, with gross margin at 37%. The company ended June with $46.8 million in cash, cash equivalents and restricted cash and no outstanding debt obligations. Updated 2026 guidance calls for total net revenue between $179.0 million and $215.0 million, a 62%–68% decline from $564.2 million in 2025, and anticipates second‑half revenue down approximately 64%–74% year over year, compared with a prior expected decline of 45%–52%.
Organogenesis Holdings Inc. reported results from its 2026 Annual Meeting of Stockholders held on June 15, 2026. Holders of 129,564,421 shares of Class A common stock, including 38,470,359 as-converted shares from Series A Convertible Preferred Stock, were represented.
Stockholders elected nine directors, including Robert Ades and Gary S. Gillheeney, Sr., each receiving over 76 million votes for, with substantial broker non-votes reflecting street-held shares. Holders of Series A Convertible Preferred Stock also re-elected Garrett Lustig to the board by written consent.
Investors approved, on an advisory basis, the compensation of named executive officers, with 72,516,011 votes for and 12,722,258 against. They also ratified the appointment of RSM US LLP as independent registered public accounting firm for fiscal year 2026, with 128,421,160 votes for and minimal opposition.
Organogenesis Holdings Inc. reported a steep downturn for the first quarter ended March 31, 2026. Net product revenue fell to $36.3 million from $86.7 million a year earlier, a 58% decline, driven by a 63% drop in Advanced Wound Care revenue to $29.5 million. Gross profit fell to $10.5 million, or 29% of net product revenue, from $63.0 million, or 73%. Operating loss widened to $68.9 million and net loss to $53.2 million, or $(0.44) per share, compared with a $18.8 million net loss, or $(0.17) per share, in 2025. Adjusted EBITDA loss increased to $48.2 million from $12.5 million. Despite the weak quarter, the company ended March 31, 2026 with $92.1 million in cash, cash equivalents and restricted cash and no outstanding debt, and issued full-year 2026 revenue guidance of $270.0 million to $310.0 million, implying a 45% to 52% decline from 2025.
Organogenesis Holdings Inc. reported record results for 2025, driven by strong growth in advanced wound care. Net product revenue for the year reached $563.0 million, up 17% from 2024, with advanced wound care contributing $531.2 million. Net income improved to $37.0 million from $0.9 million, and Adjusted EBITDA nearly doubled to $98.1 million.
In the fourth quarter of 2025, net product revenue rose 78% to $225.1 million, and net income jumped to $43.7 million. Gross margin remained strong at 76% for the year. The company ended 2025 with $94.3 million in cash, cash equivalents and restricted cash and no outstanding debt obligations.
For 2026, management expects total net revenue between $350.0 million and $420.0 million, a decline of 25% to 38% from total net revenue of $564.2 million in 2025. The company anticipates a sharp revenue drop in early 2026 due to CMS reimbursement and coverage changes for skin substitutes, followed by stronger quarter-over-quarter growth later in the year and a return to more “normalized” growth in 2027.
Organogenesis Holdings Inc. has appointed Patrick McGuire, 40, as Chief Accounting Officer and principal accounting officer, effective February 18, 2026. His annual base salary was increased to $345,000, with no other changes to his compensation.
McGuire previously served as the company’s Vice President, Corporate Controller since September 2023 and earlier was Corporate Controller at Cynosure, LLC and a director at PricewaterhouseCoopers LLP. There are no family relationships or related-party transactions requiring disclosure. Concurrently, David Francisco ceased serving as principal accounting officer but continues as Chief Financial Officer and principal financial officer.
Organogenesis Holdings (ORGO) reported that it announced its fiscal third-quarter results for the period ended September 30, 2025, via a press release dated November 6, 2025. The company furnished the press release as Exhibit 99.1 to an 8-K.
The company stated that the press release is being furnished and is not deemed filed for purposes of Section 18 of the Exchange Act. For full details, readers are directed to the furnished Exhibit 99.1.
Organogenesis Holdings, Inc. filed a Form 8-K reporting a material event that includes a press release dated September 25, 2025 and referenced data from Phase 3 randomized controlled trials (ReNu) dated the same day. The filing indicates the press release and trial data are provided as part of the 8-K's disclosures and that the interactive cover page data are embedded in the Inline XBRL document. The filing is signed by Lori Freedman, Chief Administrative and Legal Officer.
The filing text supplied here contains no actual trial results, financial figures, forward-looking statements, or additional narrative about the ReNu data, and therefore does not disclose outcomes, metrics, or impacts on operations or finances.
Organogenesis Holdings Inc. (Nasdaq: ORGO) filed an 8-K covering the results of its 23 June 2025 Annual Meeting and a preferred-stock director election.
Board & Executive Matters
- Series A Convertible Preferred holders unanimously re-elected Garrett Lustig to the Board.
- All nine management-nominated directors were re-elected; the highest support was 72.4 million votes (95.8% of votes cast) for Gilberto Quintero, while the lowest was 68.9 million (93.9%) for Jon Giacomin.
- Say-on-Pay advisory resolution passed with 91.4% support (67.1 m for / 6.3 m against).
Capital Structure Proposal
- Shareholders approved—by 45.4 m for vs. 2.7 m against—the potential issuance of >20% of outstanding Class A shares upon conversion of Series A Preferred below Nasdaq “minimum price,” a step that could be deemed a change-of-control under Rules 5635(b)/(d).
Audit Matters
- RSM US LLP was ratified as independent auditor for FY 2025 with 96.4% support (103.6 m for / 3.9 m against).
Quorum: 107.5 million Class A votes were present (inclusive of 25.4 m as-converted preferred shares, subject to Nasdaq’s 19.99% cap).
The filing is largely routine governance disclosure; however, the preferred-stock conversion approval introduces potential future dilution that current shareholders should monitor.